一分钟看懂
这是一项关于淋巴瘤的II 期 / III 期研究，登记的药物或干预包括Selinexor (combination therapy)；Placebo matching for Selinexor (combination therapy)；Rituximab (combination therapy)；Gemcitabine (combinatio，当前状态为研究进行中，已停止招募。登记地点显示中国南京、苏州、Huangpu、徐汇区等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Selinexor (combination therapy)；Placebo matching for Selinexor (combination therapy)；Rituximab (combination therapy)；Gemcitabine (combination therapy)；Dexamethasone (combination therapy)；Cisplatin (combination therapy)；Selinexor (continuous therapy)；Placebo matching for Selinexor (continuous therapy) · II 期 / III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Jiangsu Province Hospital · 南京
- The First Affiliated Hospital of Soochow University · 苏州
- Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School · Huangpu
- Zhongshan Hospital Fudan University · 徐汇区
- Huaxi Hospital Sichuan University · 成都
- The first affiliated Hospital, Zhejiang University · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Have pathologically confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma). Patient with high-grade lymphoma with c-MYC, Bcl2 and/or Bcl6 rearrangements are eligible (only for Phase 2). (Documentation to be provided).
- * Have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL with relapsed or refractory disease following their most recent regimen.
- Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of systemic therapy.
- Maintenance therapy will not be counted as a separate line of systemic therapy.
- Radiation with curative intent for localized DLBCL will not be counted as 1 line of systemic therapy.
- * Positron emission tomography (PET) positive measurable disease with at least 1 node having the longest diameter (LDi) greater than (\>) 1.5 centimeter (cm) or 1 extranodal lesion with LDi \>1 cm (per the Lugano Criteria 2014). The Deauville 5-point scale (D5PS) score assessed on the FDG PET/CT should be between 3 to 5.
- * Not intended for HSCT or CAR-T cell therapy based on objective clinical criteria determined by the treating physician. Patients who cannot receive HSCT due to active disease are allowed on study (up to approximately 15 percent \[%\] of patients enrolled in each Phase). Documentation on lack of intention to proceed to receive HSCT or CAR-T therapy must be provided by the treating physician.
- * Adequate bone marrow function at screening, defined as:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04442022；登记信息更新于 2026-10-02；本站同步于 2026-10-08。